Showing papers in "European Journal of Cancer in 2002"

TL;DR: Cancer incidence and mortality estimates for 1995 are presented for the 38 countries in the four United Nations-defined areas of Europe, using World Health Organization mortality data and published estimates of incidence from national cancer registries to demonstrate the very substantial burden of cancer in Europe, and the scope for prevention.

TL;DR: The EORTC QLQ-C30 has become the most widely used questionnaire in Europe for cancer patients, and is extensively used around the world as mentioned in this paper. But it is not suitable for all patients.

TL;DR: Although the prediction of malignancy in this tumor group is notoriously difficult, tumors that have mitotic activity counts exceeding 5 per 50 high power fields (HPF) or those larger than 5 cm have a high frequency of intra-abdominal recurrence and liver metastasis and are likely to be benign, these diagnostic criteria leave an inevitable gray area in the separation of benign and malignant tumors.

TL;DR: This review focuses on fatigue observed in patients during and after treatment for cancer, using data from empirical studies that indicate that fatigue is mostly studied during active treatment forcancer, and is an important problem during this period.

TL;DR: Department of Pathology, University Hospital Antwerp, Edegem, AntwerP, Belgium Division of Medical Oncology, Azienda Complesso Ospedaliero ‘‘San Filippo Neri’’, Rome, Italy

TL;DR: The role played by APC is discussed in providing, when mutated, selective advantage, through constitutional activation of the Wnt signal transduction pathway, and chromosomal instability to the nascent intestinal tumor cell.

TL;DR: Estimated progression-free rates (PFR) for various groups of soft-tissue sarcoma patients from the authors' clinical trials database are provided to provide reference values for conducting phase II studies with PFR as the principal end-point.

TL;DR: D detection of specific viral mRNAs derived from integrated HPV genomes in advanced precancers can be used to identify lesions with a particularly high risk for progression into invasive carcinomas (APOT assay) and new markers will result in a modified classification of cervical precancers and improved screening assays.

TL;DR: Patients with metastatic colorectal cancer clearly preferred oral over i.v. 5-FU treatment, and taking the medication at home, less stomatitis and diarrhoea, and pill over injection as the most important reasons for their preference.

TL;DR: CK20/7 phenotyping of adenocarcinomas is a useful diagnostic tool if based on algorithmic and probabilistic approaches and a detailed database.

TL;DR: The observed alterations in the expression of ECM proteins in breast cancer tissue and their correlations with the proteolytic enzyme CD and the adhesion molecule CD44s, suggest an involvement in cancer progression.

TL;DR: The combination of anti-VEGF-R and anti-EGF-R therapies was effective in inhibiting gastric cancer growth and support the hypothesis that inhibiting multiple biological pathways that mediate tumour growth may be an effective therapeutic strategy.

TL;DR: Imatinib has shown activity in vivo against PDGF-driven tumor models including glioblastoma, dermatofibrosarcoma protuberans and chronic myelomonocytic leukemia, and is also a potent inhibitor of the Kit receptor tyrosine kinase.

TL;DR: PET should improve the ability to accurately follow response in GIST patients treated with imatinib mesylate, and permit this new therapeutic approach to be used optimally with accurate follow-up assessments and informed therapeutic decision-making.

TL;DR: Results show that the juxtamembrane region of Eph receptors is important in receptor autoregulation, and it is likely that dysregulation of other modular components of signaling pathways also plays a role in oncogenic transformation.

TL;DR: The relationship between molecular biology and drug discovery methods, as utilized for the identification of anticancer drugs, will be illustrated and focused on issues of target selectivity, cellular efficacy, therapeutic effectiveness and tolerability.

TL;DR: Patients with unresectable liver metastases should concentrate on accurate imaging of the liver lesions and the detection of extrahepatic disease, and local tumour ablation should be considered as an adjunct to hepatic resection in cases in which resection can not deal with all of the tumour lesions.

TL;DR: Baseline QoL is a strong independent predictor of survival in patients with advanced colorectal cancer and should be routinely recorded in clinical trials to stratify cohorts and aid in trial comparison.

TL;DR: In this paper, a phase I study conducted by the EORTC Soft Tissue and Bone Sarcoma Group, 40 patients with advanced soft tissue sarcomas, most of whom had gastrointestinal stromal tumors (GISTs), received imatinib at doses of 400 mg q.i.d., 400 mg b.i., or 500 mg q i.d. Dose-limiting toxicities, including severe nausea, vomiting, edema and rash, were seen at the highest dose level; the maximum tolerated dose was therefore 400 mgb.i

TL;DR: It is demonstrated in a population-based study that the prognosis for patients with UPT is more unfavourable than suggested in most clinical studies.

TL;DR: Recent developments in in vivo bioluminescence imaging (BLI) are summarized and the potential of this imaging strategy for the future of cancer research is discussed.

TL;DR: The results indicate that while EGFR overexpression is a common event in colorectal carcinogenesis, it does not influence patient prognosis and is not associated with Dukes' stage, site, patient age or gender.

TL;DR: The focus of colorectal cancer follow-up should shift from the early detection of recurrence towards quality assessment and patient support, and the search for preclinical cancer recurrence should primarily be performed by carcino-embryonic antigen testing and ultrasound.

TL;DR: Clinical knowledge of the prognosis of patients with GISTs remains rather limited--small tumor size, low-grade mitotic index and stomach location are factors associated with a more favorable prognosis.

TL;DR: The data show that NAMI-A, although undergoing a series of chemical modifications, maintains its antimetastatic activity in a broad range of experimental conditions.

TL;DR: This review is focused on three modalities, PET, MR and optical imaging which are available to the scientist for oncological investigations in animals.

TL;DR: The criteria that can predict a clinically meaningful relationship between BSA and drug clearance are discussed, and some alternative strategies to dose agents when BSA has proven to be useless are proposed.

TL;DR: In pretreated soft tissue sarcoma patients, Exatecan is well tolerated but does not achieve any objective responses, however, with respect to progression-free survival, exatecan did show some activity in leiomyosarcomas.

TL;DR: An overview of the various properties ascribed to tumour hypoxia and the current efforts underway to exploit Hypoxia for improving cancer treatment will be discussed.